Supplementation of infant formula with bovine milk fat globule membranes

Niklas Timby, Magnus Domellöf, Bo Lönnerdal, Olle Hernell

Research output: Contribution to journalReview article

13 Citations (Scopus)

Abstract

Studies have shown that supplementation of infant formula with bovine milk fat globule membranes (MFGMs) may substantially narrow the gap in health outcomes between formula-fed and breastfed infants. In one study, consumption of a formula supplemented with a lipid-rich MFGM concentrate between 2 and 6 mo ofage improved cognitive performance at 24 wkofage. In another study, a formula supplemented with a protein- rich MFGM concentrate given between 2 and 6 mo ofage improved cognitive performance at 12 mo ofage, decreased infectious morbidity until 6 mo ofage, and yielded serum cholesterol concentrations closer to those of breastfed infants. A third study that assessed the safety ofsupplementing infant formula with a lipid-rich or a protein-rich MFGM concentrate found a noninferior weight gain for both groups compared with a nonsupplemented formula. In this study, therewas an increased riskofeczema in the protein-rich group, but no seriousadverseevents. Infantformulas with supplemental MFGMs have been launched on the market in several countries. However, the evidence base must still be considered quite limited. Based on 3 randomized controlled trials that are not comparable, the intervention seems safe, but there is not enough evidence for a general recommendation on which MFGM fraction to use and at what concentration as formula supplement for a given outcome.

Original languageEnglish (US)
Pages (from-to)351-355
Number of pages5
JournalAdvances in Nutrition
Volume8
Issue number2
DOIs
StatePublished - Mar 1 2017

Fingerprint

Infant Formula
fat globules
infant formulas
milk fat
milk
Membranes
concentrates
cognition
Lipids
Proteins
feed formulation
proteins
lipids
Weight Gain
morbidity
milk fat globule
Randomized Controlled Trials
Cholesterol
weight gain
cholesterol

Keywords

  • Cholesterol
  • Cognition
  • Infant formula
  • Infection
  • MFGM
  • Neurodevelopment
  • Otitis

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Food Science
  • Nutrition and Dietetics

Cite this

Supplementation of infant formula with bovine milk fat globule membranes. / Timby, Niklas; Domellöf, Magnus; Lönnerdal, Bo; Hernell, Olle.

In: Advances in Nutrition, Vol. 8, No. 2, 01.03.2017, p. 351-355.

Research output: Contribution to journalReview article

Timby, N, Domellöf, M, Lönnerdal, B & Hernell, O 2017, 'Supplementation of infant formula with bovine milk fat globule membranes', Advances in Nutrition, vol. 8, no. 2, pp. 351-355. https://doi.org/10.3945/an.116.014142
Timby, Niklas ; Domellöf, Magnus ; Lönnerdal, Bo ; Hernell, Olle. / Supplementation of infant formula with bovine milk fat globule membranes. In: Advances in Nutrition. 2017 ; Vol. 8, No. 2. pp. 351-355.
@article{4f781847445341068337108e2201238a,
title = "Supplementation of infant formula with bovine milk fat globule membranes",
abstract = "Studies have shown that supplementation of infant formula with bovine milk fat globule membranes (MFGMs) may substantially narrow the gap in health outcomes between formula-fed and breastfed infants. In one study, consumption of a formula supplemented with a lipid-rich MFGM concentrate between 2 and 6 mo ofage improved cognitive performance at 24 wkofage. In another study, a formula supplemented with a protein- rich MFGM concentrate given between 2 and 6 mo ofage improved cognitive performance at 12 mo ofage, decreased infectious morbidity until 6 mo ofage, and yielded serum cholesterol concentrations closer to those of breastfed infants. A third study that assessed the safety ofsupplementing infant formula with a lipid-rich or a protein-rich MFGM concentrate found a noninferior weight gain for both groups compared with a nonsupplemented formula. In this study, therewas an increased riskofeczema in the protein-rich group, but no seriousadverseevents. Infantformulas with supplemental MFGMs have been launched on the market in several countries. However, the evidence base must still be considered quite limited. Based on 3 randomized controlled trials that are not comparable, the intervention seems safe, but there is not enough evidence for a general recommendation on which MFGM fraction to use and at what concentration as formula supplement for a given outcome.",
keywords = "Cholesterol, Cognition, Infant formula, Infection, MFGM, Neurodevelopment, Otitis",
author = "Niklas Timby and Magnus Domell{\"o}f and Bo L{\"o}nnerdal and Olle Hernell",
year = "2017",
month = "3",
day = "1",
doi = "10.3945/an.116.014142",
language = "English (US)",
volume = "8",
pages = "351--355",
journal = "Advances in Nutrition",
issn = "2161-8313",
publisher = "American Society for Nutrition",
number = "2",

}

TY - JOUR

T1 - Supplementation of infant formula with bovine milk fat globule membranes

AU - Timby, Niklas

AU - Domellöf, Magnus

AU - Lönnerdal, Bo

AU - Hernell, Olle

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Studies have shown that supplementation of infant formula with bovine milk fat globule membranes (MFGMs) may substantially narrow the gap in health outcomes between formula-fed and breastfed infants. In one study, consumption of a formula supplemented with a lipid-rich MFGM concentrate between 2 and 6 mo ofage improved cognitive performance at 24 wkofage. In another study, a formula supplemented with a protein- rich MFGM concentrate given between 2 and 6 mo ofage improved cognitive performance at 12 mo ofage, decreased infectious morbidity until 6 mo ofage, and yielded serum cholesterol concentrations closer to those of breastfed infants. A third study that assessed the safety ofsupplementing infant formula with a lipid-rich or a protein-rich MFGM concentrate found a noninferior weight gain for both groups compared with a nonsupplemented formula. In this study, therewas an increased riskofeczema in the protein-rich group, but no seriousadverseevents. Infantformulas with supplemental MFGMs have been launched on the market in several countries. However, the evidence base must still be considered quite limited. Based on 3 randomized controlled trials that are not comparable, the intervention seems safe, but there is not enough evidence for a general recommendation on which MFGM fraction to use and at what concentration as formula supplement for a given outcome.

AB - Studies have shown that supplementation of infant formula with bovine milk fat globule membranes (MFGMs) may substantially narrow the gap in health outcomes between formula-fed and breastfed infants. In one study, consumption of a formula supplemented with a lipid-rich MFGM concentrate between 2 and 6 mo ofage improved cognitive performance at 24 wkofage. In another study, a formula supplemented with a protein- rich MFGM concentrate given between 2 and 6 mo ofage improved cognitive performance at 12 mo ofage, decreased infectious morbidity until 6 mo ofage, and yielded serum cholesterol concentrations closer to those of breastfed infants. A third study that assessed the safety ofsupplementing infant formula with a lipid-rich or a protein-rich MFGM concentrate found a noninferior weight gain for both groups compared with a nonsupplemented formula. In this study, therewas an increased riskofeczema in the protein-rich group, but no seriousadverseevents. Infantformulas with supplemental MFGMs have been launched on the market in several countries. However, the evidence base must still be considered quite limited. Based on 3 randomized controlled trials that are not comparable, the intervention seems safe, but there is not enough evidence for a general recommendation on which MFGM fraction to use and at what concentration as formula supplement for a given outcome.

KW - Cholesterol

KW - Cognition

KW - Infant formula

KW - Infection

KW - MFGM

KW - Neurodevelopment

KW - Otitis

UR - http://www.scopus.com/inward/record.url?scp=85020185541&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020185541&partnerID=8YFLogxK

U2 - 10.3945/an.116.014142

DO - 10.3945/an.116.014142

M3 - Review article

C2 - 28298277

AN - SCOPUS:85020185541

VL - 8

SP - 351

EP - 355

JO - Advances in Nutrition

JF - Advances in Nutrition

SN - 2161-8313

IS - 2

ER -